Clinical trial
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult…
NCT05263206 · Sanofi, Industry · Recruiting
Key facts
| NCT number | NCT05263206 |
|---|---|
| Title | Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) |
| Official title | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) |
| Lead sponsor | Sanofi, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pruritus |
| Intervention type | Drug |
| Interventions | Dupilumab, Placebo, Fexofenadine (loratadine if not available) |
| Enrollment | 284 |
| Start date | Feb 15, 2022 |
| Primary completion | Jun 2, 2027 |
| Completion | Aug 25, 2027 |
| First posted | Mar 2, 2022 |
| Last update posted | Dec 17, 2025 |
| Countries | Argentina, Canada, China, Germany, Hungary, Italy, Japan, Poland, South Korea, Spain, Taiwan, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: